Viridian Therapeutics Files 8-K on Financials
Ticker: VRDN · Form: 8-K · Filed: Feb 27, 2025 · CIK: 1590750
Sentiment: neutral
Topics: financial-reporting, company-update
Related Tickers: VRDN
TL;DR
Viridian Therapeutics (VRDN) filed an 8-K on Feb 27, 2025, detailing financial results and exhibits.
AI Summary
Viridian Therapeutics, Inc. filed an 8-K on February 27, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The company, formerly known as Miragen Therapeutics, Inc. and Signal Genetics, Inc., is incorporated in Delaware and headquartered in Waltham, MA.
Why It Matters
This filing provides investors with an update on Viridian Therapeutics' financial health and operational status, which is crucial for evaluating the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine filing of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- Viridian Therapeutics, Inc. (company) — Registrant
- February 27, 2025 (date) — Date of earliest event reported
- Miragen Therapeutics, Inc. (company) — Former company name
- Signal Genetics, Inc. (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- Waltham, MA (location) — Business address
FAQ
What specific financial information is being reported in this 8-K?
The filing indicates it covers 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The earliest event reported was on February 27, 2025.
What were Viridian Therapeutics' previous company names?
Viridian Therapeutics was formerly known as Miragen Therapeutics, Inc. and Signal Genetics, Inc.
In which state is Viridian Therapeutics incorporated?
Viridian Therapeutics is incorporated in Delaware.
Where is Viridian Therapeutics' principal business address?
The company's business address is 221 Crescent Street, Suite 103A, Waltham, MA 02453.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 27, 2025 regarding Viridian Therapeutics, Inc.\DE (VRDN).